$XENE News

Full Transcript: Xenon Pharmaceuticals Q2 2026 Earnings Call

Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now

Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline

Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month

Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says

Ian Mortimer Receives the 2026 Bloom Burton Award

Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?

Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate

Xenon stock lost 30%, but the FDA story is more complicated

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment

Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data

This Biotech Surged 50% On Positive Data In March. Now, It's Completely Gone.

XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial

Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.

Xenon Pharmaceuticals falls 30% after depression trial enrollment pause

Xenon Pharmaceuticals' Azetukalner Retains Core Epilepsy Value, RBC Capital Markets Says

Xenon Stock Reaction Is Overblown: Analyst